Download
40265_2024_Article_2122.pdf 881,39KB
WeightNameValue
1000 Titel
  • Long-Term Self-Administered Outpatient Parenteral Antimicrobial Therapy in the Treatment of Tuberculosis
1000 Autor/in
  1. Rauch, A. |
  2. Köhler, Niklas |
  3. Brehm, T. T. |
  4. Zielinski, N. |
  5. Stoycheva, K. |
  6. Maier, C. |
  7. Böttcher, L. |
  8. Friesen, I. |
  9. Schaub, D. |
  10. Reimann, M. |
  11. Schmiedel, S. |
  12. Lange, C. |
  13. Kalsdorf, B. |
1000 Verlag Springer International Publishing
1000 Erscheinungsjahr 2024
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2024-12-29
1000 Erschienen in
1000 Quellenangabe
  • 85(1):87-96
1000 Copyrightjahr
  • 2024
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s40265-024-02122-4 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11739191/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Objectives!#!To investigate the safety profiles and clinical outcomes in a continuous cohort of tuberculosis (TB) patients from a clinical referral centre in Germany receiving self-administered outpatient parenteral antimicrobial therapy (sOPAT).!##!Methods!#!We conducted a retrospective observational cohort study of patients receiving sOPAT after discharge from the Research Center Borstel in Germany between January 2015 and December 2020. Data were extracted from medical records.!##!Results!#!In the observation period, 150 patients received parenteral antibiotics at the Research Center Borstel. Of these, 89 received sOPAT via a port catheter and were further analysed. The majority were male (n = 59, 66.3%), with a median age of 33.6 years (interquartile range-IQR 26.2-42.8). Most patients had multidrug-resistant (MDR)-TB (n = 56, 62.9%) or pre-extensively drug resistant (pre-XDR)-TB (n = 21; 23.6%). Fifty-eight (65.2%) patients received one and 24 patients (27.0%) received two parenteral drugs, most commonly capreomycin (n = 53, 59.6%) and meropenem (n = 44, 49.4%). The median duration of sOPAT was 7.4 months (IQR 5.2-17.2). In total, 71,128 intravenous drug administrations were recorded. One patient died of TB while another patient was lost to follow-up. Sixty-two (69.7%) patients completed the sOPAT regimen, the most common reason for premature discontinuation was adverse drug events (n = 12, 13.5%). There were eight (9.0%) port-related complications requiring port explantation (bloodstream infections: n = 6, local infection: n = 1, port thrombosis: n = 1).!##!Conclusions!#!In selected patients requiring long-term intravenous anti-TB therapy, sOPAT is a feasible treatment option with a low risk of complications when adequate infrastructure and training are in place.
1000 Sacherschließung
lokal Female [MeSH]
lokal Adult [MeSH]
lokal Humans [MeSH]
lokal Infusions, Parenteral [MeSH]
lokal Treatment Outcome [MeSH]
lokal Retrospective Studies [MeSH]
lokal Antitubercular Agents/therapeutic use [MeSH]
lokal Tuberculosis/drug therapy [MeSH]
lokal Antitubercular Agents/adverse effects [MeSH]
lokal Outpatients [MeSH]
lokal Male [MeSH]
lokal Tuberculosis, Multidrug-Resistant/drug therapy [MeSH]
lokal Antitubercular Agents/administration
lokal Germany [MeSH]
lokal Original Research Article
lokal Self Administration [MeSH]
1000 Fächerklassifikation (DDC)
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/UmF1Y2gsIEEu|https://orcid.org/0000-0002-1911-0379|https://frl.publisso.de/adhoc/uri/QnJlaG0sIFQuIFQu|https://frl.publisso.de/adhoc/uri/WmllbGluc2tpLCBOLg==|https://frl.publisso.de/adhoc/uri/U3RveWNoZXZhLCBLLg==|https://frl.publisso.de/adhoc/uri/TWFpZXIsIEMu|https://frl.publisso.de/adhoc/uri/QsO2dHRjaGVyLCBMLg==|https://frl.publisso.de/adhoc/uri/RnJpZXNlbiwgSS4=|https://frl.publisso.de/adhoc/uri/U2NoYXViLCBELg==|https://frl.publisso.de/adhoc/uri/UmVpbWFubiwgTS4=|https://frl.publisso.de/adhoc/uri/U2NobWllZGVsLCBTLg==|https://frl.publisso.de/adhoc/uri/TGFuZ2UsIEMu|https://frl.publisso.de/adhoc/uri/S2Fsc2RvcmYsIEIu
1000 Hinweis
  • DeepGreen-ID: 0d5413bf5c334ab8977428b23aef3b5d ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Förderer
  1. Deutsches Zentrum für Infektionsforschung |
  2. Forschungszentrum Borstel - Leibniz Lungenzentrum |
1000 Fördernummer
  1. -
  2. -
1000 Förderprogramm
  1. -
  2. -
1000 Dateien
1000 Förderung
  1. 1000 joinedFunding-child
    1000 Förderer Deutsches Zentrum für Infektionsforschung |
    1000 Förderprogramm -
    1000 Fördernummer -
  2. 1000 joinedFunding-child
    1000 Förderer Forschungszentrum Borstel - Leibniz Lungenzentrum |
    1000 Förderprogramm -
    1000 Fördernummer -
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6517897.rdf
1000 Erstellt am 2025-07-05T07:27:54.764+0200
1000 Erstellt von 322
1000 beschreibt frl:6517897
1000 Zuletzt bearbeitet 2025-08-19T19:18:56.885+0200
1000 Objekt bearb. Tue Aug 19 19:18:56 CEST 2025
1000 Vgl. frl:6517897
1000 Oai Id
  1. oai:frl.publisso.de:frl:6517897 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source